Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
| Company | Change | P/E (TTM) |
|---|---|---|
DEPODepoMed Inc. | -0.45% | - |
IPXLImpax Laboratories Inc. | +0.59% | 68.60 |
BIIBBiogen Inc. | +0.88% | 16.33 |
MNOVMediciNova Inc. | +5.31% | - |
ABTAbbott Laboratories | -0.36% | 23.34 |
JNJJohnson & Johnson | -0.47% | 20.39 |
LLYEli Lilly & Co. | -0.23% | 34.66 |
PFEPfizer Inc. | +0.12% | 25.10 |
TEVATeva Pharmaceutical Industries Ltd. ADR | -0.38% | 25.97 |
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company's first product gabapentin enacarbil which is known as...
| Q2 2016 Estimate Trends | |
|---|---|
| Current: | $-0.21 |
| 1 month ago: | $-0.22 |
| 3 months ago: | $-0.20 |
| Q3 2016 Estimate Trends | |
|---|---|
| Current: | $-0.15 |
| 1 month ago: | $-0.18 |
| 3 months ago: | $-0.18 |
| Mar 2016 | 5-quarter trend | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | +28.64% | | ||||||||||
| Sales or Revenue | 14.12 M | | ||||||||||
| Sales or Revenue Growth | +99.84% | | ||||||||||
| EBITDA | -13.62 M | | ||||||||||
| 2015 | 5-year trend | |||||||||||
| Net Income Growth | -66.85% | | ||||||||||
| Sales or Revenue | 41.16 M | | ||||||||||
| Sales or Revenue Growth | -12.18% | | ||||||||||
| EBITDA | -76.81 M | |